Duchenne Muscular Dystrophy Drugs Market by Product Type, Distribution Channel, End User 2024-2032
                     Global Duchenne 
Muscular Dystrophy Drugs 
Market Research and 
Forecast Report 2024-2032
Format: PDF+EXCEL
© 2023 IMARC All Rights Reserved 
About IMARC Group
In ternat ional  Market  Analys is  Research and Consul t ing Group is  a leading adv iser  on management  
s t rategy and market  research wor ldwide.  We par tner  wi th c l ients  in  a l l  regions and indust ry  
vert ica ls  to  ident i fy  thei r  h ighest -value oppor tuni t ies,  address thei r  most  cr i t ica l  chal lenges,  and 
t ransform thei r  bus inesses.
IMARC’s in format ion products  inc lude major market ,  sc ient i f ic ,  economic and technological  
developments  for  bus iness leaders  in  pharmaceut ica l ,  indust r ia l ,  and h igh technology 
organizat ions.  Market  forecasts  and indust ry  analys is  for  b iotechnology,  advanced mater ia ls ,  
chemicals ,  food and beverage,  t ravel  and tour ism, nanotechnology and novel  process ing methods 
are at  the top of  the company’s  exper t ise.
IMARC’s ta i lored approach combines unfathomable ins ight  in to the dynamics o f  companies and 
markets wi th c lose cooperat ion at  a l l  levels  of  the c l ient  organizat ion.  This ensures that  our  c l ients 
achieve unmatchable compet i t ive advantage,  bui ld  more pro f ic ient  organizat ions,  and secure 
las t ing resul ts .
A c c o r d i n g  t o  t h e  l a t e s t  r e p o r t  b y  I M A R C  G r o u p ,  t i t l e d  " D u c h e n n e  M u s c u l a r  D y s t r o p h y  
D r u g s  M a r k e t :  G lo b a l  In d u s t r y  T r e n d s ,  S h a r e ,  S i z e ,  G r o w t h ,  O p p o r t u n i t y  a n d  F o r e c a s t  
2 0 2 4 - 2 0 3 2 , "  t h e  g l o b a l  D u c h e n n e  m u s c u l a r  d y s t r o p h y  d r u g s  m a r k e t  s i z e  r e a c h e d  U S $  2 . 3  
B i l l i o n  i n  2 0 2 3 .
F a c to rs  A f fe c t in g  th e  G ro w th  o f  th e  D u c h e n n e  Mu s c u l a r  D y s t ro p h y  D ru g s  
Report I n d u s t ry :
In c re a s in g  D is e a s e  P re v a le n c e :
Highlight and T h e  i n c r e a s i n g  d e m a n d  f o r  D u c h e n n e  m u s c u l a r  d y s t r o p h y  ( D M D )  d r u g s  d u e  t o  t h e  r i s i n g  p r e v a l e n c e  o f  t h e  d i s e a s e  i s  d r i v i n g  t h e  m a r k e t  g r o w t h .  M o r e o v e r ,  w i d e  a c c e s s i b i l i t y  t o  
g e n e t i c  t e s t i n g ,  c o u p l e d  w i t h  r i s i n g  a w a r e n e s s  a m o n g  h e a l t h c a r e  p r o v i d e r s  a b o u t  D M D  
Description s y m p t o m s  a n d  g e n e t i c  m a r k e r s ,  i s  d r i v i n g  t h e  m a r k e t  g r o w t h .  E a r l y  d i a g n o s i s  i s  c r u c i a l  f o r  t h e  t r e a tm e n t  o f  D M D ,  l e a d i n g  t o  i n c r e a s e d  d e m a n d  f o r  t h e r a p e u t i c  s o l u t i o n s .  T h i s  t r e n d  
i s  o b s e r v e d  a c r o s s  t h e  g l o b e ,  n o t  o n l y  i n  d e v e l o p e d  c o u n t r i e s  b u t  a l s o  i n  r e g i o n s  w h e r e  
g e n e t i c  t e s t i n g  a n d  h e a l t h c a r e  i n f r a s t r u c t u r e  a r e  i m p r o v i n g .
T e c h n o lo g ic a l  A d v a n c em e n ts  in  T re a tme n t :
I n n o v a t i o n s  i n  g e n e  t h e r a p y  a n d  m o l e c u l a r  m e d i c i n e  a r e  o p e n i n g  u p  n e w  o p p o r t u n i t i e s  f o r  
t h e  t r e a t m e n t  o f  D M D .  T e c h n i q u e s  s u c h  a s  C R I S P R  g e n e  e d i t i n g  a n d  e x o n  s k i p p i n g  e n a b l e  
t h e  c o r r e c t i o n  o f  g e n e t i c  a b n o r m a l i t i e s  t h a t  c a u s e  D M D  a t  t h e  m o l e c u l a r  l e v e l .
These advanced therap ies ,  whi le  a t  vary ing s tages of  research and 
tes t ing,  promise potent ia l ly  t ransformat ive  improvements in  pat ient  
outcomes.  These technolog ies  are not  on ly  dr iv ing investment  f rom 
pharmaceut ica l  companies,  but  a lso p iqu ing in terest  f rom regula tors  and 
investors ,  acce lerat ing the pace of  research and t r ia ls  a imed at  f ind ing a 
cure or  more ef fect ive t reatments  for  DMD.
Advancements in Drug Del ivery Systems:
Report In  DMD, pat ients  may have l imi ta t ions re la ted to  musc le  weakness and 
damage,  and innovat ive drug de l ivery  technolog ies  that  are less  invas ive 
Highlight and and more ef f ic ient  can make a d i f ference.  The development  o f  susta ined-
re lease formulat ions,  t ransdermal  patches or  nanopar t ic le-based de l ivery 
Description systems can improve the way drugs are admin is tered,  enhanc ing  the i r  
absorpt ion and reduc ing s ide e f fec ts.  
In  l ine wi th  th is ,  improved drug de l ivery  systems are therefore a  dec is ive 
fac tor ,  mak ing t reatment  opt ions more to lerab le  and potent ia l ly  e f fec t ive,  
thus increasing the i r  adopt ion and market  expansion wor ldwide.
Request  for  a  PDF sample of  th is  report :  
ht tps : / /www. imarcgroup.com/duchenne-muscular -dyst rophy-drugs-market / r
equestsample
Report Description
Global  Duchenne Muscular  Dystrophy Drugs Market  Trends:
Government  agenc ies in  severa l  count r ies are o f fer ing var ious incent ives to  encourage the development  o f  
t reatments  for  rare d iseases such as DMD. These inc lude var ious laws that  o f fer  benef i ts  such as tax  
cred i ts ,  user  fee waivers ,  and market  exc lus iv i ty  for  up to  seven years  a f ter  approval .  These incent ives 
make i t  economica l ly  v iab le  for  pharmaceut ica l  companies to  invest  in  d iseases wi th  re la t ive ly  smal l  
pat ient  popula t ions.  
Th is  suppor t  is  c ruc ia l  to  boost ing the development  and rap id  approval  o f  new drugs,  as i t  o f fsets  the h igh 
costs  and r isks  associa ted wi th  pharmaceut ica l  development  in  rare d iseases.  In  addi t ion to  th is ,  r is ing 
heal thcare expendi ture and the wi l l ingness of  insurance companies to  cover  h igh-cost  t reatments  for  rare 
d iseases cont r ibute to  the growth of  the market .
View Report  TOC,  Figures and Tables :  
ht tps: / /www.imarcgroup.com/duchenne-muscular -dystrophy-drugs-market
Product Type Insights:
• Cort icosteroids
o Prednisolone
o Prednisone
o Defl azacort
• Pain Management Drugs
Report 
Therapeutic Approach Insights:
Segmentation
• Mutation Suppression
• Exon Skipping 
• Steroid Therapy
End User Insights:
• Hospitals
• Clinics
• Home Care Settings
Breakup by Region:
• North America
Report • Asia-Pacifi c
• Europe
Segmentation • Latin America
• Middle East and Afr ica
• FibroGen Inc.
• I tal farmaco S.p.A.
• NS Pharma Inc. (Nippon Shinyaku Co. Ltd.)
Competitive • PTC Therapeutics Inc.
• Santhera Pharmaceuticals
Landscape 
• Sarepta Therapeutics Inc.
with Key 
Players
How big is the global Duchenne muscular dystrophy drugs 
market?
What is the expected growth rate of the global Duchenne 
muscular dystrophy drugs market during 2024-2032?
What are the key factors driving the global Duchenne 
muscular dystrophy drugs market?
Key 
What has been the impact of COVID-19 on the global 
Duchenne muscular dystrophy drugs market?
Questions 
What is the breakup of the global Duchenne muscular 
Answered in dystrophy drugs market based on the product type?
the Report What is the breakup of the global Duchenne muscular dystrophy drugs market based on the therapeutic approach?
What is the breakup of the global Duchenne muscular 
dystrophy drugs market based on the end user?
What are the key regions in the global Duchenne muscular 
dystrophy drugs market?
Who are the key players/companies in the global Duchenne 
muscular dystrophy drugs market?
1     P r e f a c e
2     S c o p e  a n d  M e t h o d o l o g y
    2 . 1     O b j e c t i v e s  o f  t h e  S t u d y
    2 . 2     S t a k e h o l d e r s
    2 . 3     D a t a  S o u r c e s
        2 . 3 . 1     P r i m a r y  S o u r c e s
        2 . 3 . 2     S e c o n d a r y  S o u r c e s
    2 . 4     M a r k e t  E s t i m a t i o n
        2 . 4 . 1     B o t t o m - U p  A p p r o a c h
Table of         2 . 4 . 2     T o p - D o w n  A p p r o a c h    2 . 5     F o r e c a s t i n g  M e t h o d o l o g y
3     E x e c u t i v e  S u m m a r y
4     I n t r o d u c t i o n
    4 . 1     O v e r v i e w
Contents     4 . 2     K e y  I n d u s t r y  T r e n d s5     G l o b a l  D u c h e n n e  M u s c u l a r  D y s t r o p h y  D r u g s  M a r k e t
    5 . 1     M a r k e t  O v e r v i e w
    5 . 2     M a r k e t  P e r f o r m a n c e
    5 . 3     I m p a c t  o f  C O V I D - 1 9
    5 . 4     M a r k e t  F o r e c a s t
6     M a r k e t  B r e a k u p  b y  P r o d u c t  T y p e
    6 . 1     C o r t i c o s t e r o i d s
        6 . 1 . 1  M a r k e t  T r e n d s
        6 . 1 . 2  K e y  S e g m e n t s
           6 . 1 . 2 . 1  P r e d n i s o l o n e
           6 . 1 . 2 . 2  P r e d n i s o n e
           6 . 1 . 2 . 3  D e f l a z a c o r t
        6 . 1 . 3  M a r k e t  F o r e c a s t
    6 . 2     P a i n  M a n a g e m e n t  D r u g s
        6 . 2 . 1  M a r k e t  T r e n d s
        6 . 2 . 2  M a r k e t  F o r e c a s t
       
7     M a r k e t  B r e a k u p  b y  T h e r a p e u t i c  A p p r o a c h
    7 . 1     M u t a t i o n  S u p p r e s s i o n
        7 . 1 . 1  M a r k e t  T r e n d s
        7 . 1 . 2  M a r k e t  F o r e c a s t
    7 . 2     E x o n  S k i p p i n g
        7 . 2 . 1  M a r k e t  T r e n d s
        7 . 2 . 2  M a r k e t  F o r e c a s t
    7 . 3     S t e r o i d  T h e r a p y
        7 . 3 . 1  M a r k e t  T r e n d s
        7 . 3 . 2  M a r k e t  F o r e c a s t
8     M a r k e t  B r e a k u p  b y  E n d  U s e r
Table of     8 . 1     H o s p i t a l s
        8 . 1 . 1  M a r k e t  T r e n d s
        8 . 1 . 2  M a r k e t  F o r e c a s t
Contents     8 . 2     C l i n i c s        8 . 2 . 1  M a r k e t  T r e n d s
        8 . 2 . 2  M a r k e t  F o r e c a s t
    8 . 3     H o m e  C a r e  S e t t i n g s
        8 . 3 . 1  M a r k e t  T r e n d s
        8 . 3 . 2  M a r k e t  F o r e c a s t
9     M a r k e t  B r e a k u p  b y  R e g i o n
    9 . 1     N o r t h  A m e r i c a
        9 . 1 . 1  U n i t e d  S t a t e s
           9 . 1 . 1 . 1  M a r k e t  T r e n d s
           9 . 1 . 1 . 2  M a r k e t  F o r e c a s t
        9 . 1 . 2  C a n a d a
           9 . 1 . 2 . 1  M a r k e t  T r e n d s
           9 . 1 . 2 . 2  M a r k e t  F o r e c a s t
F o r  m o r e  i n f o r m a t i o n ,  v i s i t :  
ht t ps : / /w ww. i ma rc gro up . c o m /d uc henn e -m u sc u l a r-d ys t ro phy -d
rug s -m a rke t / t o c
Partial List of Clients
Partial List of Clients
Disclaimer
© 2024  IMARC Al l  R ights  Reserved 
Th is  Pub l i ca t ion  and  a l l  i t ’ s  con ten ts  un less  o therw ise  men t i oned  a re  copy r i gh ted  in  the  name o f  
I n t e rna t i ona l  Marke t  Ana lys i s  Research  and  Consu l t ing  ( IMARC) .  No  pa r t  o f  t h i s  pub l i ca t ion  may  be  
rep roduced ,  repackaged ,  red i s t r i bu ted  o r  res o ld  i n  who le  o r  i n  any  pa r t .  The  pub l i ca t ion  may  a l so  
no t  be  used  i n  any  f o rm o r  by  and means  g raph i c  e lec t ron ic  o r  mechan ic a l ,  i nc lud ing  pho tocopy ing ,  
reco rd ing ,  t ap ing  o r  by  i n fo rmat i on  s to rage  o r  re t r ieva l ,  o r  by  any  o the r  f o rm,  w i t hou t  the  exp ress  
c ons en t  o f  I n t e rna t iona l  Marke t  Ana lys i s  Research  and  Consu l t i ng  ( IMARC) .
Disc la imer :  Al l  con ten ts  and  da ta  o f  t h i s  pub l i c a t i on ,  i nc lud ing  fo recas t s ,  da ta  ana lys i s  and  op in ion  
have  been  based  on  in f o rmat ion  and  sources  be l ieved  to  be  accu ra te  and  re l iab le  a t  t he  t ime  o f  
pub l i sh ing .  In t e rna t i ona l  Ma rke t  Ana l ys is  Research  and  Consu l t ing  makes  no  rep resen ta t ion  o f  
war ran t y  o f  any  k ind  as  to  t he  acc u racy  o r  comp le teness  o f  any  I n fo rmat i on  p rov ided .  IMARC 
accep ts  no  l i ab i l i t y  wha tsoever  f o r  any  los s  o r  damage  resu l t i ng  f rom op in ion ,  e r ro rs  o r  
i naccu rac ies  i f  any  f ound  th is  pub l i ca t ion .
IMARC,  IMARC Group  and  G loba l  Therapy  I ns igh t  Ser i es  a re  reg is t e red  t rademarks  o f  I n te rna t iona l  
Marke t  Ana lys i s  Research  and  Consu l t ing .  A l l  o the r  t rademarks  used  i n  th i s  pub l i ca t i on  a re  
reg i s te red  t rademarks  o f  t he i r  r espec t i ve  compan ies .
Contact Us
Visit us at :
https://www.imarcgroup.com
+1-631-791-1145
[email protected]
Stay With Us: